ATE339226T1 - Zellabgabeflüssigkeit zur verhinderung von zellablagerungen in abgabesystemen - Google Patents

Zellabgabeflüssigkeit zur verhinderung von zellablagerungen in abgabesystemen

Info

Publication number
ATE339226T1
ATE339226T1 AT03741809T AT03741809T ATE339226T1 AT E339226 T1 ATE339226 T1 AT E339226T1 AT 03741809 T AT03741809 T AT 03741809T AT 03741809 T AT03741809 T AT 03741809T AT E339226 T1 ATE339226 T1 AT E339226T1
Authority
AT
Austria
Prior art keywords
cell
density
delivery
deposits
specific gravity
Prior art date
Application number
AT03741809T
Other languages
English (en)
Inventor
Mary M Morris
Brian C A Fernandes
Stanton C Spear
Matthew A Bergan
Kenneth C Gardeski
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Application granted granted Critical
Publication of ATE339226T1 publication Critical patent/ATE339226T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3895—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Fuel Cell (AREA)
  • Optical Measuring Cells (AREA)
AT03741809T 2002-05-22 2003-05-22 Zellabgabeflüssigkeit zur verhinderung von zellablagerungen in abgabesystemen ATE339226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38276402P 2002-05-22 2002-05-22
US10/442,525 US20040067221A1 (en) 2002-05-22 2003-05-21 Cell delivery fluid for prevention of cell settling in delivery system

Publications (1)

Publication Number Publication Date
ATE339226T1 true ATE339226T1 (de) 2006-10-15

Family

ID=29586968

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03741809T ATE339226T1 (de) 2002-05-22 2003-05-22 Zellabgabeflüssigkeit zur verhinderung von zellablagerungen in abgabesystemen

Country Status (9)

Country Link
US (1) US20040067221A1 (de)
EP (1) EP1506027B1 (de)
JP (1) JP2005525914A (de)
AT (1) ATE339226T1 (de)
AU (1) AU2003273131B2 (de)
CA (1) CA2486173A1 (de)
DE (1) DE60308357T2 (de)
ES (1) ES2271612T3 (de)
WO (1) WO2003099347A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287125A1 (en) * 2002-05-22 2005-12-29 Medtronic, Inc. Cell delivery fluid for prevention of cell settling in delivery system
US8685724B2 (en) * 2004-06-01 2014-04-01 Kwalata Trading Limited In vitro techniques for use with stem cells
KR100802011B1 (ko) 2005-08-10 2008-02-12 인하대학교 산학협력단 층분리배양법을 이용한 골수에서의 중간엽 줄기세포분리방법
US20070048288A1 (en) * 2005-08-30 2007-03-01 Lyu Suping Shear thinning polymer cell delivery compositions
JP2007175008A (ja) * 2005-12-28 2007-07-12 Hiroshima Univ 幹細胞の培養方法
US8784800B2 (en) * 2009-03-09 2014-07-22 Medtronic, Inc. Method of delivering cell therapy to a target site
GB201521784D0 (en) 2015-12-10 2016-01-27 Univ Birmingham Cell purification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5543316A (en) * 1994-04-20 1996-08-06 Diacrin, Inc. Injectable culture medium for maintaining viability of myoblast cells
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
WO1999003973A1 (en) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6171610B1 (en) * 1998-04-24 2001-01-09 University Of Massachusetts Guided development and support of hydrogel-cell compositions
GB9822158D0 (en) * 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
DE10119522A1 (de) * 2001-04-20 2002-12-05 Innovacell Biotechnologie Gmbh Herstellung und Anwendung einer Suspensionszusammensetzung mit einem Ultraschall-Kontrastmittel
JP3934539B2 (ja) * 2001-12-12 2007-06-20 独立行政法人科学技術振興機構 胎盤等由来の成体又は生後組織の前駆細胞

Also Published As

Publication number Publication date
DE60308357D1 (de) 2006-10-26
ES2271612T3 (es) 2007-04-16
DE60308357T2 (de) 2007-09-06
JP2005525914A (ja) 2005-09-02
US20040067221A1 (en) 2004-04-08
EP1506027A1 (de) 2005-02-16
AU2003273131B2 (en) 2007-05-03
EP1506027B1 (de) 2006-09-13
WO2003099347A1 (en) 2003-12-04
CA2486173A1 (en) 2003-12-04
AU2003273131A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
Seitaj et al. Cable bacteria generate a firewall against euxinia in seasonally hypoxic basins
Floodgate et al. Microbiological and zooplankton activity at a front in Liverpool Bay
ATE395934T1 (de) Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen
ATE156968T1 (de) Stall mit entmistungsgraben mit v-förmigem boden und verfahren zur reduzierung von ammoniak- emission
NZ333786A (en) Bioreactor for mammalian cells comprising a flow restrictor which maintains the cell density at near tissue levels
BR0213805A (pt) Células estromais derivadas de tecido adiposo para diferenciação endócrina do pâncreas e usos das mesmas
DE68920433D1 (de) Regelventile.
Pedersen et al. Adaptations of submerged Lobelia dortmanna to aerial life form: morphology, carbon sources and oxygen dynamics
NZ511062A (en) Antagonists of alpha4 containing integrins, which inhibit the biological effects of adhesion interaction in myeloma bone disease
ATE324030T1 (de) Brassica-transformation durch teilchenbeschuss
DE60308357D1 (de) Zellabgabeflüssigkeit zur verhinderung von zellablagerungen in abgabesystemen
DE60032153D1 (de) Trägermaterial zum wachsen von zellen
CA2543118A1 (en) Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease
EP1179183A4 (de) Verfahren zum identifizieren von präneoplastischen und neoplastischen stadien in säugern
IL174488A0 (en) Bioartificial implant and its use and method of reducing the risk for formation of connective tissue after implantation
WO2007019055A3 (en) Cell delivery fluid for prevention of cellsettling in delivery system
BR0110474A (pt) Métodos para remover células neoplásticas mediadas por ras de uma composição celular, para preparar uma composição celular para transplante em um receptor e para reduzir um risco de recorrência de tumor, e, composição celular
CY1109815T1 (el) Μεθοδοι διασταυρουμενης συμβατοτητας ειδικες δοτη
IL178265A (en) Tissue-like organization of cells, macroscopic tissue-like constructs generated by macromass culture of cells and the method of macromass culture
DE602004009218T8 (de) Verfahren zur abscheidung von zink oder zinklegierungen
ATE385503T1 (de) Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
ATE394660T1 (de) Verfahren zum immunzytologischen oder molekularen nachweis von disseminierten tumorzellen aus einer körperflüssigkeit und dazu geeigneter kit
TW200641897A (en) Write-once read-many times memory
ATE519772T1 (de) Vorrichtung und system mit trockener kontrollgen- verstummungszusammensetzung
RU2006108180A (ru) Способ комплексного биотестирования воды, почвы, биологически активных веществ в фитотестах

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties